Epstein Secrets

ve and quantitative information about investment processes ■ Regular meetings with investors ■ Investments by partners and employees comprise 7% of Och-Ziff's AUMI ■ Och-Ziff's partners receive a substantial majority of their compensation from distributions tied to profitability As of September I. 2015 u

ios, valuation and risk management Highlights Successfully closed 12 U.S. CLOs with a total transaction value of approximately $7.0 billion Led by Brett Klein, Head of U.S. Corporate Credit, and Donald Young, Senior Portfolio Manager, Institutional Credit Strategies, with significant and broad expertise in

Mount Sinai Medical Center. Harold Kelly is Head of Global Convertible and Derivative Arbitrage and Risk Management for Och-Ziff and is a member of Och-Ziff's Partner Management Committee. Mr. Kelly is also an Executive Managing Director. Prior to joining Och-Ziff in 1995, Mr. Kelly spent seven years tradi

Partners, Ltd. Mr. Kelly holds a B.B.A. in Finance and also holds an M.B.A. and a Ph.D. in Business Administration from the University of Georgia. Brett Klein is an Executive Managing Director and Head of U.S. Corporate Credit for Och-Ziff. Mr. Klein oversees performing and distressed credit investments in

Mount Sinai Medical Center. Harold Kelly is Head of Global Convertible and Derivative Arbitrage and Risk Management for Och-Ziff and is a member of Och-Ziff's Partner Management Committee. Mr. Kelly is also an Executive Managing Director. Prior to joining Och-Ziff in 1995, Mr. Kelly spent seven years tradi

Partners, Ltd. Mr. Kelly holds a B.B.A. in Finance and also holds an M.B.A. and a Ph.D. in Business Administration from the University of Georgia. Brett Klein is an Executive Managing Director and Head of U.S. Corporate Credit for Och-Ziff. Mr. Klein oversees performing and distressed credit investments in